secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001437749-23-003637
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics Q4 revenue falls 35% to $1.84M, net loss $2.9M; merger completed
--------------------------------------------------------------------------------

- Revenue down 35% YoY to $1.84M; prostate brachytherapy sales dropped 50% due to lost largest customer orders.
- Net loss $2.9M ($0.02/share) vs $1.6M ($0.01) last year; operating expenses rose to $3.7M from $2.86M.
- Gross margin plunged to 22.0% from 43.3%, driven by lower prostate sales volume.
- Cash & equivalents $43.8M, no debt; stockholders' equity $55.0M.
- Completed merger with Viewpoint Molecular Targeting on Feb 3; name changed to Perspective Therapeutics; ticker to CATX on Feb 21.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774923003637/0001437749-23-003637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774923003637/isr20230215_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-003637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer